Your Health, We Care
The most common (≥ 20%) adverse reactions are:
1.As a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, constipation.
2.In combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.
from FDA，2023.09
Cabozantinib is a small-molecule multi-targeted tyrosine kinase inhibitor develo···【more】
Release date：2026-03-20Recommended：50
Cabozantinib is a broad‑spectrum multi‑targeted anticancer drug that inhibits at···【more】
Release date：2026-03-20Recommended：41
After administration, necessary therapeutic effects may occur, and adverse react···【more】
Release date：2026-02-05Recommended：63
Cabozantinib is a widely used drug for the treatment of a variety of cancers, an···【more】
Release date：2025-02-21Recommended：220
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that has demonstrated···【more】
Release date：2025-02-21Recommended：270
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that has shown signif···【more】
Release date：2025-02-20Recommended：261
